Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 33,111 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 2 Interventional Results available

SPI-1005 for the Treatment of Patients With Meniere's Disease

NCT03325790
View directory record Official record
Conditions
Meniere's Disease
Interventions
200mg SPI-1005 BID, 400mg SPI-1005 BID, Placebo
Drug · Other
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Fresno, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 28, 2026, 9:32 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

NCT01674010
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
ELND005, Lamotrigine, Valproic acid, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

NCT01120184
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
62
States / cities
Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Results available

A Study Of CP-690,550 In Stable Kidney Transplant Patients

NCT01710033
View directory record Official record
Conditions
Kidney Transplant
Interventions
Placebo, CP-690,550 5 mg BID, CP-690,550 15 mg BID, CP-690,550 30 mg BID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Oct 28, 2026, 9:32 PM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

NCT03449147
View directory record Official record
Conditions
Chronic Cough
Interventions
Placebo, Gefapixant 15 mg BID, Gefapixant 45 mg BID
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Peoria, Arizona • Phoenix, Arizona • Tempe, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

NCT00672958
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
30
States / cities
Birmingham, Alabama • Cerritos, California • Encino, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 28, 2026, 9:32 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

NCT04421248
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Combined
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Donald Gilbert, MD, MS, FAAN, FAAP
Other
Eligibility
8 Years to 12 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 9:32 PM EDT
Not listed Phase 1 Interventional

The Gut-Brain Study

NCT03426826
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Gastro-Intestinal Disorder
Interventions
FMT versus placebo
Biological
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.

NCT02229578
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

NCT01037985
View directory record Official record
Conditions
Scar Prevention
Interventions
EXC 001, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
La Jolla, California • Chicago, Illinois • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 28, 2026, 9:32 PM EDT
Recruiting Not applicable Interventional

Prehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis

NCT07029243
View directory record Official record
Conditions
Cirrhosis, Frailty, Sarcopenia
Interventions
HEAL-ME digital app, Creatine supplementation, Whey protein supplementation, Placebo
Behavioral · Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

NCT02665143
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
Nintedanib and AML induction
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
New Haven, Connecticut • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Not applicable Interventional Results available

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

NCT02461225
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Erchonia® FX-635™, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)

NCT03310125
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery
Interventions
Active Colchicine, Active Placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
3,209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Weston, Florida • Detroit, Michigan • Stony Brook, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

NCT00076076
View directory record Official record
Conditions
Asthma
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
39
States / cities
Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in Arkansas, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

NCT00811889
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
Interventions
Placebo, Bardoxolone Methyl (RTA 402)
Other · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Montgomery, Alabama • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

NCT03982368
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 85 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Glendale, California • Newport Beach, California • Rancho Cordova, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Not applicable Interventional

Study of TNF-Antagonism in Metabolic Syndrome

NCT00409318
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

NCT01215149
View directory record Official record
Conditions
HIV Infections
Interventions
Ad35-ENV vaccine, Ad26.ENVA.01 vaccine, Placebo Control
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

NCT03292458
View directory record Official record
Conditions
Spasmodic Dysphonia, Voice Tremor
Interventions
Sodium Oxybate
Drug
Lead sponsor
Kristina Simonyan
Other
Eligibility
21 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 28, 2026, 9:32 PM EDT
Withdrawn Phase 3 Interventional

Transversus Abdominis Plane (TAP) Block for Post Caesarian Pain

NCT01986049
View directory record Official record
Conditions
Obstetrical Complications From Sedation During Parturition
Interventions
Bupivicaine
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 28, 2026, 9:32 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs (Inpatient): 38

NCT03954938
View directory record Official record
Conditions
Cocaine Use, Unspecified
Interventions
Craving Manipulation, Cocaine, Placebo
Behavioral · Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 28, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370538
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Mobile, Alabama • San Francisco, California • Westlake Village, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 28, 2026, 9:32 PM EDT